Randomized controlled trial of twice-a-day administration of natural interferon β for chronic hepatitis C

Hepatology Research

Volumn 18, Issue 3, 2000, Pages 310-319

  Yoshioka, Kentaro ^a   Yano, Motoyoshi ^a   Hirofuji, Hideo ^b   Arao, Motohiro ^c   Kusakabe, Atsuhiko ^d   Sameshima, Yoichi ^d   Kuriki, Junsuke ^e   Kurokawa, Susumu ^f   Murase, Kenichi ^f   Ishikawa, Tetsuya ^g   Kakumu, Shinichi ^f  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yokkaichi Municipal Hospital   (Japan)

^c Inazawa Municipal Hospital   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^e Gamagori City Hospital   (Japan)

^f CHUBU ROSAI HOSPITAL   (Japan)

^g AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Genotype; Hepatitis C virus; Multivariate analysis; Predictors of response; Viral load

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; LYMPHOBLAST INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FLUSHING; HEARING DISORDER; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0033809513     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(00)00080-2     Document Type: Article

References (22)

1. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome
2. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
3. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
4. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial
5. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
6. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
7. Interferon-alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response
8. Long-term carrier state of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C
9. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C
10. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon β
11. Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy
12. Efficacy of the combination therapy using twice-a-day IFN-β followed by IFN-α2b in the treatment for chronic hepatitis C
13. Randomized control trial of interferon-β injection at 12-h intervals as a therapy for chronic hepatitis C
14. Diseases of The Liver And Biliary Tract: Standardization of Nomenclature, Diagnostic Criteria And Diagnostic Methodology
15. Classification of chronic hepatitis: Diagnosis, grading and staging
16. Significance of specific antibody assay for genotyping of hepatitis C virus
17. Sequence variability in the 5' non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity
18. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses
19. Randomized controlled trial of lymphoblastoid interferonα for chronic hepatitis C (comparison of 9-MU and 6-MU doses)
20. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
21. Predictive factors in the response to interferon therapy in chronic hepatitis C
22. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus